Here are five notes:
1. The company’s sentiment was 1.19 in the fourth quarter of 2015.
2. NuVasive has a market cap of $3.01 billion and a P/E ratio of 124.97.
3. During the last trading session, NuVasive shares hit $59.97 per share, up 0.42 percent.
4. Since November, the company’s shares have increased 14.85 percent.
5. NuVasive shares have outperformed the S&P500 by 14.38 percent.
More articles on devices:
Bioventus files for $150M IPO: 5 points
United Orthopedic Corp. teams up with Dr. Freddy Achecar to offer TKR, THR to underserved in China: 4 notes
Prosidyan, MO-SCI collaborate on new orthopedic technology — 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
